Search
IRESSA 250 MG, Comprimé pelliculé
Details
| --- | Description |
|---|---|
| Pack | Boite de 30 |
| Strength (Dosage) | 250 MG |
| Laboratory | MAPHAR |
| Ingredients | Géfitinib |
| Therapeutic class | Inhibiteurs de protéine kinase antinéoplasiques |
| ATC code | L01XE02 |
| PPH | $1,804.80 |
| PPV | $1,840.00 |
| Refundable | Yes |
| Refund base | $1,840.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Medication |
| Uses | Géfitinib est indiqué chez les adultes dans le traitement du cancer bronchique non à petites cellules (CBNPC) localement avancé ou métastatique avec mutations activatrices de l'EGFR-TK. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem